Adagrasib oral dose of 400 mg twice daily tablets

Phase 2

Mirati Therapeutics, Inc. (MRTX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '26

MRTXPhase 2

Adagrasib oral dose of 400 mg twice daily tablets Phase 2 Est. Readout

Adagrasib oral dose of 400 mg twice daily tablets• Advanced NSCLC90

Sep 2026~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in Advanced NSCLC

View Full Landscape

Drug Information

Target Indication

Advanced NSCLC

Clinical Trial

NCT05609578

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/5/2024

Krazati

Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRTX

Mirati Therapeutics, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

AdagrasibPhase 3

Carcinoma, Non-Small-Cell Lung

MRTX849Phase 3

Advanced Cancer

SitravatinibPhase 3

Clear Cell Renal Cell Carcinoma

mFOLFOX6 RegimenPhase 3

Advanced Colorectal Cancer

AZD4547Phase 2

Non-Small Cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts